<DOC>
	<DOCNO>NCT00545311</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics , pharmacodynamics safety multiple dos NVA237 mild moderate COPD patient .</brief_summary>
	<brief_title>Safety Tolerability Multiple Inhaled NVA237 Doses Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male and/or female patient age 4075 year age mild moderate COPD . Diagnosis mild/moderate COPD , accord GOLD guideline . Bronchodilatory response ipratropium screen Current exsmokers smoke history &gt; 10 packyears . Ten packyears define 20 cigarette day 10 year , 10 cigarette day 20 year etc . Female patient must surgically sterilize least 6 month prior screen : Postmenopausal woman must regular menstrual bleeding least 1 year prior inclusion . Lab postbronchodilator value within certain range . Body mass index ( BMI ) must within range 18 32 kg/m2 . Any significant medical condition opinion Investigator may compromise patient safety , patient compliance , interfere evaluation , preclude completion trial . Any medical condition may make spirometry unsafe History glaucoma , symptomatic prostatism urinary retention . Participation clinical investigation within 4 week prior dose longer required local regulation limitation participation base local regulation . Previous participation study either investigational comparator drug exclude patient participation study . Donation loss 400 ml blood within 8 week prior first dose , longer required local regulation . Significant illness ( respiratory illness ) within two week prior dose . Clinically significant ECG abnormality indicative unstable underlying cardiac problem , e.g . recent myocardial infarction , 2nd/3rd degree heart block , family history grandparent , parent sibling prolong QTinterval syndrome . History clinically significant drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug . History immunocompromise , include positive HIV ( ELISA Western blot ) test result . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation . Patients unable demonstrate appropriate use Concept 1 device screen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>multiple inhale , NVA237 , COPD</keyword>
</DOC>